This study presents a new approach to targeting the mitochondrial gatekeeper VDAC1 using a newly developed VDAC1-interacting small molecule, VBIT-4, to treat AD pathology in a mouse model. The gene discussed is VDAC1; the disease is Alzheimer disease.